Epitalon for Adults 65 and Older: What Geriatric Patients Need to Know About Transitioning to This Peptide

What epitalon is, and what it is not

Epitalon is a synthetic four-amino-acid peptide, Ala-Glu-Asp-Gly, with a molecular weight of about 390 g/mol as the free base and about 450 g/mol as the acetate [1]. It was designed from the amino-acid content of epithalamin, a polypeptide extract of animal pineal gland, and FDA says it first appears to have been synthesized in 1999 [1].

Epithalamin and epitalon are not interchangeable. FDA treats them as different substances, so studies of the pineal extract are not studies of the synthetic peptide [1].

Epitalon is sold online as research-use-only vials of 10 mg to 50 mg, as capsules and as oral sprays, and marketed as an anti-aging peptide that lengthens telomeres [1]. It received an FDA orphan drug designation for retinitis pigmentosa on September 2, 2010; that designation was withdrawn on January 6, 2016 [1].

What the human studies actually measured

FDA found only three human studies of epitalon: two using a sublingual spray in night-shift workers and one using an injection beside the eye in retinitis pigmentosa. None were in insomnia [1].

One of the sublingual studies enrolled 75 healthy women aged 40 to 50, most of them night-shift workers; 40 had low melatonin output and were split into two groups of 20 [1]. They took a sublingual spray delivering about 0.5 mg per day, or placebo, for 20 days. Urinary 6-sulfatoxymelatonin rose about 1.7-fold on epitalon and did not change on placebo, and 83% versus 25% were described as improved in mood and physical condition. No sleep outcomes were measured, blinding was not specified, and the study was short and small [1].

The retinitis pigmentosa work is an older controlled clinical study in which epitalon was injected beside the eye; the abstract reports a 'positive clinical effect in 90% of the cases' but gives no sample sizes or design details, and the result has not been replicated [6].

A 2026 narrative review that searched the literature through September 22, 2026 reached the same conclusion: human evidence is limited to small physiological or biomarker studies plus that older eye study, no adequately powered randomized trial has established efficacy, and pharmacokinetic, dose-ranging and long-term safety data are inadequate. The authors called epitalon 'biologically active but clinically unproven' [5].

The telomere claim comes from cells in a dish

Adding epitalon to telomerase-negative human fetal fibroblast cultures induced the catalytic subunit of telomerase, telomerase activity and telomere elongation [7]. That is a cell-culture result. FDA found no study showing epitalon extends life or slows aging in people [1].

Is there a dose for a 65-year-old?

No. There is no approved dose [1]. Websites FDA reviewed suggest 5 mg to 10 mg per day by subcutaneous injection or orally, in cycles, with one site suggesting a course every four months; these are seller suggestions, not evidence [1]. The human studies FDA located used a sublingual spray delivering about 0.5 mg per day for 20 days, and a parabulbar injection beside the eye for retinitis pigmentosa [1].

No dose-finding study in older adults, and no age, frailty or kidney-function adjustment, has been identified.

Safety in older adults

FDA did not identify clinical data establishing epitalon's safety, and found no pharmacokinetic data, so how the peptide is absorbed or cleared is not known [1]. Its search of the adverse-event database through December 8, 2025, and of the food and supplement complaint system through December 5, 2025, retrieved no epitalon reports [1]. The familiar claim that epitalon has 'no side effects' traces to a Russian-language abstract that gave no dose, route or number of people [1].

FDA also raised an immunogenicity concern for subcutaneous injection; injectable peptides may pose immunogenicity risk from aggregation and impurities [8][1].

The telomerase and cancer question

FDA warned that epitalon activates telomerase and lengthens telomeres, that longer telomeres are generally linked to higher cancer risk, and that the peptide therefore has a mechanistic potential to be carcinogenic [1]. The mouse cancer and chromosome-damage studies FDA reviewed were too limited to establish safety: one fixed dose, female mice only, short exposure [1].

One mouse study reported a different result. Female HER-2/neu transgenic mice given 1 microgram per mouse for 5 consecutive days each month from age 2 months had a reduced cumulative number and maximum size of mammary tumors (P<0.05) and a 3.7-fold lower expression of HER-2/neu mRNA in tumors than saline-treated animals [9]. It is a mouse study at a fixed microgram dose, not evidence of cancer safety in people.

Where compounding and the law stand

FDA lists epitalon in the 'nominated but withdrawn' table of its page on bulk substances that may present significant safety risks. FDA's stated concern is that it 'has not identified safety-related information regarding epitalon for the proposed route of administration,' and removal from the higher-risk category was not a finding that the substance is safe [8]. Epitalon appears in none of the three categories on FDA's interim lists for state-licensed pharmacies and physicians (updated May 14, 2026) or for outsourcing facilities (updated March 21, 2025), so the agency's category 1 no-action policy does not cover it [10][11][12].

In July 2026, FDA staff proposed that neither epitalon free base nor epitalon acetate be added to the compounding bulks list. FDA evaluated only the insomnia use, since the anti-aging and telomere uses were not evaluated for lack of information, and cited that epitalon is not well characterized, limited historical use, no evidence of effectiveness for insomnia, no clinical safety data, immunogenicity concern for subcutaneous injection, and the existence of many approved insomnia drugs [1]. FDA's Pharmacy Compounding Advisory Committee reviewed epitalon on July 24, 2026 and voted in favor of adding it, against staff's recommendation. That vote is advice only, and epitalon is not on the list; adding it would take formal rulemaking [2][3].

Separately, HHS filed a draft enforcement-discretion policy on October 28, 2026 (Federal Register document 2026-22192, publication scheduled October 30, 2026, comments due two weeks after publication) naming epitalon among six peptides [3][4]. It covers epitalon acetate given subcutaneously or intramuscularly in intermittent courses, and says HHS 'does not intend to take enforcement action' against a state-licensed pharmacy, federal facility or licensed physician compounding with it if conditions are met: a single active ingredient, a patient-specific prescription, an FDA-registered manufacturer with a certificate of analysis, and a label reading 'This is a compounded drug product. Not for resale.' [3][4]. The notice states that it does not establish rights for any person and is not binding on HHS or the public. Compounded drugs are not FDA-approved: FDA does not review their safety, effectiveness or quality before marketing [3].

What this means for a person 65 or older

No approved dose, age-specific dose adjustment or dose-ranging data exist for older adults. What exists is a draft HHS statement about which prescribers it says it would not pursue, and a non-binding advisory vote [3][4][2].

A person 65 or older who asks about epitalon is asking about an unapproved peptide sold online as research vials, capsules and sprays and, under the draft HHS policy, as a compounded injection [1][3]. Vials sold online, capsules and sprays are not the forms the draft policy covers; it applies only to epitalon acetate given by subcutaneous or intramuscular injection in intermittent courses [3][4].